Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer - Concepedia

Concepedia

Publication | Closed Access

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

47

Citations

27

References

2017

Year

Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen, Howard A. Burris, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Scott M. Hynes,

Cancer Chemotherapy and Pharmacology

Advanced CancerOncologyMedicineEg5 InhibitorPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyPhase 1Cancer ResearchDrug Discovery

References

	Year	Citations

Page 1

Page 1